CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • ASCO 2022 Recap: Cancer Immunotherapy Updates

    Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought…
    June 13, 2022| Arthur N. Brodsky, PhD
  • What to Expect in Cancer Immunotherapy in 2021: COVID-19, Biomarkers, and Clinical Trial Design

    Dr. Kunle Odunsi shares his thoughts on what lies ahead for the field of cancer immunotherapy.

    April 6, 2021| Arthur N. Brodsky, PhD
  • How Immunotherapy for Esophageal Cancer is Making an Impact

    Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…

    April 27, 2020| Arthur N. Brodsky, PhD
  • ASCO19 Recap: Caring for Every Patient, Learning from Every Patient

    ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…

    June 7, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies

    The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…

    June 2, 2019| Arthur N. Brodsky, PhD
  • AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care

    AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…

    April 5, 2019| Arthur N. Brodsky, PhD
  • AACR19 Day 4 Update: The Microbiome, Immunotherapy Biomarkers, and New Immune Targets

    Day 4 of AACR19 explored the microbiome and its impact on cancer treatment, revealed insights into immunotherapy…

    April 2, 2019| Arthur N. Brodsky, PhD
  • IO360 2019 Preview: Collaboration, Investment, Clinical Trials, and Combinations

    The fifth annual Immuno-Oncology 360° conference will be held on February 6-8, 2019 in New York City.

    February 1, 2019| Arthur N. Brodsky, PhD
  • How Immunotherapy Is Making an Impact in Liver Cancer

    We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…

    December 21, 2018| Arthur N. Brodsky, PhD
1 2 3
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute